# Palatin Targets First-Half 2027 Start for Lead Lipidated MC4R Peptide

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/59843
Published: 2026-11-17T21:00:17.000Z
Updated: 2026-11-17T21:00:17.000Z
Section: Business

> Fiscal 2027 first-quarter priorities included IND-enabling activities for the peptide and development of oral small-molecule candidates.

Palatin Technologies, Inc. is targeting a Phase 1 study of its lead lipidated MC4R peptide in the first half of calendar 2027, while advancing work on oral candidates in its drug-development programs.

The company’s fiscal 2027 first-quarter priorities included IND-enabling activities for the peptide and development of oral small-molecule candidates.

Palatin is targeting the study for the first half of calendar 2027. The update describes work on the peptide as ongoing.


